Their use provides an effective treatment to the NSCLC patients protecting the L858R activating mutation; however, their prolonged use imparts T790M mutation (gatekeeper residue mutation) in the kinase domain of EGFR, leading to the development of resistance in 60% of patients [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.